Etravirine: the renaissance of non-nucleoside reverse transcriptase inhibitors

Bibliography

• Fauci Anthony. Opinion Assay 26 Years of HIV. Nature 2008;453:289-90
   PubMedGoogle Scholar
• Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003;362:22-9
   PubMed Web of Science ®Google Scholar
• Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60
   PubMed Web of Science ®Google Scholar
• Gazzard B. on behalf of the BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV infected adults with antiretroviral therapy (2006). HIV Med 2006;7:487-503
   PubMed Web of Science ®Google Scholar
• Hammer SM, Saag MS, Schechter M, et al. Treatment for Adult HIV infection: 2006 recommendations of the International Aids Society-USA panel. JAMA 2006;296:827-43
   PubMed Web of Science ®Google Scholar
• Guidelines for the use of antiretroviral agents in HIV-1-Infected adults and adolescents January 29th 2008. Available from: http://AIDSinfo.nih.gov on June 1st 2008
   Google Scholar
• Riddler SA, Haubrich R, Di Rienzo G, et al. A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection: ACTG 5142. XVI International AIDS Conference [abstract THLB0204]. Toronto, Canada; 2006
   Google Scholar
• Bacheler L, Jeffrey S, Hanna G, et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing non-nucleoside reverse transcriptase inhibitor therapy. J Virol 2001;75:4999-5008
   PubMed Web of Science ®Google Scholar
• Delaugerre C, Rohban R, Simon A, et al. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol 2001;65:445-4814
   PubMed Web of Science ®Google Scholar
• Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999;341:1865-73
   PubMed Web of Science ®Google Scholar
• Tashima K, Staszewski S, Nelson M, et al. Durable viral suppression on EFV-based HAART: 168 weeks of follow-up. XV International AIDS Conference [abstract TuPeB4547]. Bangkok, Thailand; 2004
   Google Scholar
• Van Leth F, Phanuphak P, Ruxungtham K, et al. 2NN Study Team. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN Study. Lancet 2004;363:1253-63
   PubMed Web of Science ®Google Scholar
• DeJesus E, Young B, Fisher A, et al. Virologic suppression is maintained after change to efavirenz/emtricitabine/tenofovir disoproxil fumarate single tablet regimen (EFV/FTC/TDF) vs. continuation of current antiretroviral therapy: Study 073 -Results of 24-week interim efficacy analyses. 11th European AIDS Conference (EACS) [abstract (late-breaker) PS7/6]. October 24-27; Madrid, Spain; 2007
   Google Scholar
• Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation non-nucleoside reverse transcriptase inhibitor active against non-nucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004;48(12):4680-6
   PubMed Web of Science ®Google Scholar
• Tantillo C, Ding J, Jacobo-Molina A, et al. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol 1994;243(3):369-87
   PubMed Web of Science ®Google Scholar
• Ding J, Das K, Moereels H, et al. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse non-nucleoside inhibitors. Nat Struct Biol 1995;2(5):407-15
   PubMedGoogle Scholar
• Bacheler LT. Resistance to non-nucleoside inhibitors of HIV-1 reverse transcriptase. Drug Resist Updat 1999;2(1):56-67
   PubMedGoogle Scholar
• Das K, Clark AD Jr, Lewi PJ, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004;47(10):2550-60
   PubMed Web of Science ®Google Scholar
• Hsiou Y, Ding J, Das K, et al. Structure of unliganded HIV-1 reverse transcriptase at 2.7 a resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure 1996;4(7):853-60
   PubMed Web of Science ®Google Scholar
• Das K, Lewi PJ, Hughes SH, Arnold E. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of nonnucleosideHIV-1 reverse transcriptase inhibitors. Prog Biophys Mol Biol 2005;88(2):209-31
   PubMed Web of Science ®Google Scholar
• Knoll MB, Vento S, Temesgen Z. Etravirine. Drugs Today 2008;44(1):23-33
   PubMed Web of Science ®Google Scholar
• Schöller M, Hoetelmanns R, Beets G, et al. Substantial improvement of oral bioavailability of TCM125 using new tablet formulations in healthy volunteers. Program and abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment [abstractTuPe3.1B11]. July 24-27; Rio de Janeiro, Brazil; 2005
   Google Scholar
• Schöller-Gyure M, Leemans R, Beets G, et al. Effect of food on the oral bioavailability of the phase III formulation of TMC125. Program and abstracts of the 7th International Workshop on Clinical Pharmacology of HIV Therapy [abstract 80]. Lisbon, Portugal; 2006
   Google Scholar
• Gruzdev B, Rakhmanova A, Doubovskaya E, et al. A randomized, double-blind, placebo controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS 2003;17(17):487-94
   PubMedGoogle Scholar
• Etravirine, prescribing information distributed by Tibotec Therapeutics, Division of Ortho Biotech Products, L.P. Raritan, NJ. January 2008. Available from: http://www. ttmedicalinformation.com ttmedicalinformation/ assets /INTELENCE_PI.pdf
   Google Scholar
• Gazzard BG, Pozniak AL, Rosenbaum W, et al. An open-label assessment of TMC125, a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 2003;17(18):F49-54
   PubMed Web of Science ®Google Scholar
• Schöller-Gyüre M, Kakuda TN, De Smedt G, et al. Pharmacokinetics of TMC125 in once- and twice-daily regimens in HIV-1-negative volunteers. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy [Poster # A-1427]. September 17 – 20; Chicago, IL, USA; 2007
   Google Scholar
• Kakuda TN, Wade JR, Snoeck E, et al. Pharmacokinetics and pharmacodynamics of the NNRTI etravirine (ETR; TMC125) in treatment-experienced HIV-1–infected patients: pooled 24–week results of DUET-1 and DUET-2. Poster presented at the 15th Conference on Retroviruses and Opportunistic Infections (CROI) [abstract 762]. February 3-6; Boston, MA; 2008
   Google Scholar
• Baede P, Piscitelli S, Graham N, et al. Drug interactions with TMC125, a potent next generation NNRTI. Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy [abstract A-1827]. September 27-30; San Diego, California; 2002
   Google Scholar
• Kakuda TN, Scholler-Gyure M, Peeters M, et al. Pharmacokinetics of etravirine (ETR; TMC125) are not affected by sex, age, race, use of enfuvirtide (ENF) or treatment duration in HIV-1–infected subjects. Poster presented at the 9th International Workshop on Clinical Pharmacology of HIV Therapy (IWCPHIV) [abstract 34]. April 7-9; New Orleans, LA; 2008
   Google Scholar
• De Bethune MP, Hertogs K, Azijn H, et al. TMC 125, a third generation non nucleoside reverse transcriptase inhibitor, inhibits 98% of more than 2,000 recombinant HIV clinical isolates at 100 nM. Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy [abstract 219]. September 17-20; Toronto, Canada; 2000
   Google Scholar
• Harris M, Zala C, Ramirez S, et al. Pharmacokinetics and safety of addingTMC125 to stable regimens of saquinavir, lopinavir, ritonavir, and NRTI in HIV+ adults. Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections [abstract 575b]. Denver, Colorado; 2006
   Google Scholar
• Woodfall B, Vingerhoets J, Peeters M, et al. Impact of NNRTI and NRTI resistance on the response to the regimen of TMC125 plus two NRTIs in Study TMC125-C227. 8th International Congress on Drug Therapy in HIV Infection. November 12-16; Glasgow; 2006. Oral presentation PL5.6
   Google Scholar
• Montaner J, Domingo P, Junod P, et al. Safety and tolerability of TMC125 in 3-class experienced HIV-infected patients: 24-week primary analysis of trial TMC125-C203. Program and abstracts of the European AIDS Clinical Society 10th European AIDS Conference [abstract LBPS3/7B]. November 17-20; Dublin, Ireland; 2005
   Google Scholar
• Lazzarin A, Arribas J, Pozniak A, et al. Sustained antiviral activity of TMC125 plus optimized antiretroviral therapy in highly treatment-experienced patients. Program and abstracts of the 7th International Congress on Drug Therapy in HIV Infection [abstract 316]. November 14-18; Glasgow, Scotland; 2004
   Google Scholar
• Writing Group TMC125-C223, Nadler JP, Berger DS, Blick G, et al. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. AIDS 2007;21(6):F1-10
   Google Scholar
• Cohen C, Steinhart C, Ward D, et al. Efficacy and safety results at 48 weeks with the novel NNRTI, TMC125, and impact of baseline resistance on the virologic response in study TMC125-C223. Program and abstracts of the XVI International AIDS Conference [abstract TUPE0061]. August 13-18; Toronto, Canada; 2006
   Google Scholar
• Madruga JV, Cahn P, Grinsztejn B, et al. DUET-1 study group. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomized, double-blind, placebo-controlled trial. Lancet 2007;370(9581):29-38
   PubMed Web of Science ®Google Scholar
• Lazzarin A, Campbell T, Clotet B, et al. DUET-2 study group. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomized, double-blind, placebo-controlled trial. Lancet 2007;370(9581):39-48
   PubMed Web of Science ®Google Scholar
• Trottier B, Johnson M, Katlama C, et al. Pooled 48-Week analysis of DUET-1 and DUET-2: durable efficacy and safety results of etravirine (ETR; TMC125) in treatment-experienced HIV-infected patients. 17th Annual Canadian Conference on HIV/AIDS Research (CAHR) [abstract 167]. April 24-27; Montréal, Canada; 2008
   Google Scholar
• Johnson M, Campbell T, Clotet B, et al. DUET-2:Week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETR; TMC125) versus placebo in 591 treatment-experienced HIV-1-infected patients. 15th Conference on Retroviruses and Opportunistic Infections (CROI) [abstract 791]. February 3-6; Boston, MA; 2008
   Google Scholar
• Gatell J, Beatty G, Johnson M, et al. Impact of TMC125, a Next-generation NNRTI, on Clinical Outcomes (AIDS-defining Illnesses and Deaths): 24-week Findings from a Planned Pooled Analysis of the DUET Studies [abstract P7.3/18]. 11th EACS 2007
   Google Scholar
• Hirschel B, Pernege T, Editorial Comment. No patient left behind–better treatments for resistant HIV infection. Available from: www.thelancet.com, 2007;370:3-5
   Google Scholar
• Peeters M, Nijs S, Vingerhoets J, et al. Determination of phenotypic clinical cut-offs for etravirine (ETR): pooled Week 24 results of the DUET-1 and DUET-2 trials 11th European AIDS Conference (EACS) [abstract 121]. October 24-27; Madrid, Spain; 2007
   Google Scholar
• Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: Evidence from in vitro selection experiments. J Virol 2005;79(20):12773-82
   PubMed Web of Science ®Google Scholar
• Bacheler LT. Resistance to non-nucleoside inhibitors of HIV-1 reverse transcriptase. Drug Resist Updat 1999;2(1):56-67
   PubMedGoogle Scholar
• Udier-Blagovic M, Tirado-Rives J, Jorgensen WL. Validation of a model for the complex of HIV-1 reverse transcriptase with non-nucleoside inhibitor TMC125. J Am Chem Soc 2003;125(20):6016-7
   PubMedGoogle Scholar
• Vingerhoets J, Clotet B, Peeters M, et al. Impact of baseline NNRTI mutations on the virologic response to TMC125 (etravirine, ETR) in the DUET-1 and DUET-2 Phase III clinical trials. 11th European AIDS Clinical Society (EACS) Conference [abstract P7.3/05]. October 24-27; Madrid, Spain; 2007
   Google Scholar
• Vingerhoets J, Peeters M, Azijn H, et al. An update of the list of NNRTI mutations associated with decreased virologic response to etravirine (ETR): multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data. XVIIth International Drug Resistance Workshop [abstract # 24]. June 10-14; Sitges, Spain; 2008
   Google Scholar
• Winters B, Villacian J, Van Craenenbroeck E, et al. Development of VircoTYPE HIV-1 resistance analysis, including clinical cutoffs for TMC125 (etravirine, ETR), a new NNRTI. 15th Conference on Retroviruses and Opportunistic Infections (CROI) [abstract 873]. February 3-6; Boston, MA; 2008
   Google Scholar
• Picchio G, Vingerhoets J, Staes M, et al. Prevalence of etravirine (ETR, TMC125) resistance-associated mutations in a large panel of clinical isolates. 15th Conference on Retroviruses and Opportunistic Infections [abstract 866]. February 3-6; Boston, MA; 2008
   Google Scholar
• Lapadula G, IIzzo i, Gargiulo F, et al. Updated Prevalence of Genotypic Resistance Among HIV-1 Positive Patients Naive to Antiretroviral Therapy: A Single Center Analysis. J Med Virol 2008;80:747-53
   PubMedGoogle Scholar
• Picchio G, Vingerhoets J, Parkin N. Nucleoside-associated mutations cause hypersusceptibility to etravirine (ETR). XVIIth International Drug Resistance Workshop [abstract 23]. June 10-14; Sitges, Spain; 2008
   Google Scholar
• Janssen PA, Lewi PJ, Arnold E, Daeyaert F, et al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl] -2,6-dimethylphenyl] amino]-2-pyrimidinyl]amino] benzonitrile (R278474, rilpivirine). J Med Chem 2005;48(6):1901-9
   PubMed Web of Science ®Google Scholar
• Pozniak A, Morales-Ramirez J, Mohapi, et al. 48-Week Primary Analysis of Trial TMC278-C204: TMC278 Demonstrates Potent and Sustained Efficacy in ART-naïve Patients. 15th Conference on Retroviruses and Opportunistic Infections (CROI 2008) [abstract 134]. February 3-6; Boston, MA; 2008. Boston, MA. February 3-6, 2008. Abstract 144 LB
   Google Scholar
• van't Klooster G, Verloes R, Baert L, et al. Long-acting TMC278, a Parenteral Depot Formulation Delivering Therapeutic NNRTI Concentrations in Preclinical and Clinical Settings. Long-acting TMC278, the Parenteral Formulation Depot Delivering Therapeutic NNRTI Concentrations in Preclinical and Clinical Settings. 15th Conference on Retroviruses and Opportunistic Infections (CROI 2008). 15th Conference on Retroviruses and Opportunistic Infections (CROI 2008) [abstract 134]. February 3-6; Boston, MA; 2008
   Google Scholar
• Goebel F, Yakovlev A, Pozniak AL, et al. Short-term antiviral activity of TMC278 – a novel NNRTI – in treatment-naive HIV-1-infected subjects. AIDS 2006;20(13):1721-6
   PubMed Web of Science ®Google Scholar
• David Cooper, Gatell J, Rockstroh J, at el. Results of BENCHMRK-1, a Phase III Study Evaluating the Efficacy and Safety of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus. 14th Conference on Retroviruses and Opportunistic Infections [abstract 788]. Los Angeles, CA; 2007
   Google Scholar
• Nelson M, Fatkenheuer G, Konourina I, et al. Efficacy and Safety of Maraviroc plus Optimized Background Therapy in Viremic, ART-experienced Patients Infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-Week Results. 14th Conference on Retroviruses and Opportunistic Infections [abstract 104aLB]. Los Angeles, CA; 2007
   Google Scholar
• Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and Safety of Maraviroc plus Optimized Background Therapy in Viremic ART-experienced Patients Infected with CCR5-tropic HIV-1: 24-Week Results of a Phase 2b/3 Study in the US and Canada. 14th Conference on Retroviruses and Opportunistic Infections [abstract 104bLB]. Los Angeles, CA; 2007
   Google Scholar